Nuvation Bio Inc. has recently released its 10-Q report, providing a detailed insight into its financial condition and business operations. The clinical-stage biopharmaceutical company, founded in 2018 and headquartered in New York, focuses on developing therapeutic candidates for oncology, with its lead product candidate being taletrectinib, an ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. The company is also developing Safusidenib, NUV-1511, and NUV-868, targeting various advanced solid tumors.
In the 10-Q report, Nuvation Bio discusses its financial overview, stating that since its inception in 2018, it has primarily focused its resources on research and development activities, resulting in accumulated net losses of $1,023.0 million as of June 30, 2025. The company anticipates continuing to incur significant expenses and increasing operating losses over the next several years, particularly as it advances product candidates through clinical trials and pursues regulatory approval. Nuvation Bio expects its expenses to substantially increase in connection with its ongoing activities, including operating as a public company and continuing research activities for the discovery of new product candidates.
The report also outlines recent developments, including the approval of IBTROZI for the treatment of adult patients with locally advanced or metastatic ROS1+ NSCLC by the U.S. Food and Drug Administration in June 2025. Additionally, Nuvation Bio closed a non-dilutive financing of up to $250.0 million from Sagard, with $150.0 million funded upon the FDA's approval of IBTROZI, supporting the U.S. launch of the drug and general corporate purposes.
In terms of revenues, Nuvation Bio reported total revenues of $4.8 million for the three months ended June 30, 2025, compared to $1.4 million for the same period in 2024. This revenue consisted of $1.2 million in product revenue, net from U.S. sales of IBTROZI, and $3.6 million in collaboration and license agreements revenue, which increased by $2.2 million from the prior year. The market has reacted to these announcements by moving the company's shares -0.85% to a price of $2.33. For more information, read the company's full 10-Q submission here.
